China VC Watch: Genome, Diagnostics Ventures Attract New Funding
Executive Summary
Genetron Health is the latest emerging Chinese biotech to attract new capital in the push toward precision medicine in China, while the Lilly Asia Fund is among the investors in cancer diagnosis venture Singlera’s Series A.
You may also be interested in...
M&A Analysis: Grail's Chinese Merger Wraps Up Busy May
It was a robust month for medtech M&A deal making with 17 deals in May, making it the busiest month of the year to date. The total number of acquisitions beat the number recorded in May last year and picked up slightly from the 14 deals inked in the previous month.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.